Avacta Group (AVCT)

 

AVCT Share PerformanceMore

52 week high127.00 25/01/16
52 week low69.00 13/12/16
52 week change -44.97 (-38.77%)
4 week volume491,425 28/12/16

Media for (AVCT)

Presenter: Dr. Alastair Smith
31/07/2014
Presenter: Dr. Alastair Smith
06/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Result of Annual General Meeting

RNS Number: 7412U Avacta Group PLC 20 January 2017 20 January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Result of Annual General Meeting Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that at the Annual General Meeting held earlier today, all resolutions were duly pas...

Avacta sees substantial progress

Avacta Group has made substantial progress in the past year in demonstrating the performance and differentiation of its ...

Trading Update

RNS Number: 6699U Avacta Group PLC 20 January 2017 20 January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") AGM business update and notice of results Substantial progress in therapeutic programme Multiple third party technology evaluations ongoing Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and resea...

Avacta CEO to present at London forum

Avacta Group chief executive Alastair Smith will be presenting at the London Growth and Innovation Forum on 31 Janua...

Presenting at London Growth and Innovation Forum

RNS Number: 8476T Avacta Group PLC 11 January 2017 11 th January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to present at the London Growth and Innovation Forum Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, w...

Avacta Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017

Avacta Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017 Alastair Smith, CEO of Av...

Director Dealing and Issue of Equity

RNS Number: 3746T Avacta Group PLC 05 January 2017 05 January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Director Dealing and Issue of Equity Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that application has been made for 4,340 new ordinary shares of 10p each (the "N...

Director/PDMR Shareholding

RNS Number: 2886S Avacta Group PLC 20 December 2016 20 December 2016 Avacta Group plc ("Avacta" or "the Group" or "the Company") Director/PDMR Shareholding Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces the following changes to the equity incentives of its Chief Executive Officer, Alastair...

Fundamental DataMore

EPS-6.86
Dividend yield0 %

Equity Research (AVCT)

hardman & co
Avacta Group Plc
02/11/2016
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...
hardman & co
Avacta Group Plc
17/10/2016
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a revolutionary alternative to the...
hardman & co
Avacta Group Plc
19/07/2016
Avacta is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and animals. The group’s Affimer...

Latest discussion posts More

  • Re: Finncap

    what does Corporate mean? see http://www.stockopedia.com/content/what-does-quotcorporate-rating-reaffirmed-by-analystsquot-mean-101287/#comments Typically they'll issue ...
    14-Jan-2017
    Proverbs 26 vs 5
  • Finncap

    I know they are our joint broker and nomad but as at 09/01/17 recently noted as ?Reiterates? with the recommendation being set at ?CORPORATE? today by analysts at finnCap. ...
    12-Jan-2017
    mol42
  • Hardman Jan 17

    monthly Expanding opportunities for Affimers Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and ...
    11-Jan-2017
    mol42

Users' HoldingsMore

Users who hold Avacta Group also hold..
LLOYDS GRP.23%
ROCKHOPPER15%
BARCLAYS14%
ROYAL BANK SCOT13%
RENEURON11%

Codes & Symbols

ISINGB00BYYW9G87
SymbolsAVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT